Lucentis 0.5 mg/0.05 mL (10 mg/mL) injection Images
Generic Name: ranibizumab
This medication has been identified as Lucentis 0.5 mg/0.05 mL (10 mg/mL) injection. It is supplied by Genentech, Inc.
Lucentis is used in the treatment of Diabetic Macular Edema; Myopic Choroidal Neovascularization; Diabetic Retinopathy; Macular Degeneration; Macular Edema Following Retinal Vein Occlusion and belongs to the drug class anti-angiogenic ophthalmic agents. Risk cannot be ruled out during pregnancy. Lucentis 0.5 mg/0.05 mL (10 mg/mL) injection is not a controlled substance under the Controlled Substances Act (CSA).
Images of medication

Lucentis
- Generic Name
- ranibizumab
- Strength
- 0.5 mg/0.05 mL (10 mg/mL) injection
- Availability
- Prescription only
- Drug Class
- Anti-angiogenic ophthalmic agents
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Genentech, Inc.
- National Drug Code (NDC)
- 50242-0080
More about Lucentis (ranibizumab ophthalmic)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (15)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: anti-angiogenic ophthalmic agents
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.